

EMIRATINGS EXECUTIVE PAY **SCORECARD**

Data & analysis provided by GMI Ratings-The Independent Leader in Corporate Governance and ESG&A

30 Apr 2012

Human Genome Sciences, Inc.

HGSI NASDAQ

Biotechnology Market Capitalization USD: \$2,401.94 mm

CONCERN LEVEL: AVERAGE

- 1 The CEO's total remuneration is within the typical market range for the relevant industry and market cap.
- 2 The ratio between the CEO's pay and the median pay of the other named executive officers is 3X or less.
- The CEO's annual cash incentives rose or fell in line with annual performance.

1

- 4 The CEO received no more than one annual cash bonus this fiscal year.
- 5 The CEO's equity remuneration reflected the company's share price movement over the last five years.
- 6 The company only pays long-term incentives to the CEO for above median performance against a peer group.
- 7 The company's dilution from equity incentives is 10 percent or less.

1

8 Unvested equity lapses when the CEO's employment is terminated.

1

- The CEO's potential cash severance payment is capped at two times annual cash remuneration.
- The accrued benefits of the CEO's post-retirement income are within the typical market range for the relevant market cap bracket.

CEO: H. Thomas Watkins Age: 59 CEO Since: 2004

	2009	2010	2011
Base Salary	\$700,000	\$716,923	\$736,923
Discretionary Bonus	\$0	\$0	\$0
Annual Cash Incentive	\$1,050,000	\$550,000	\$200,000
Benefits and Perquisites	\$30,501	\$150,225	\$32,320
TOTAL ANNUAL COMPENSATION	\$1,780,501	\$1,417,148	\$969,243
Increase in Post-Retirement Benefits	\$0	\$0	\$0
Stock Option Awards	\$131,100	\$8,438,175	\$6,087,080
Stock Awards	\$0	\$0	\$0
TOTAL COMPENSATION	\$1,911,601	\$9,855,323	\$7,056,323
Median of Other Named Executive Officers Total Compensation	\$946,841	\$3,853,121	\$2,434,042
Value Realized on Exercise of Stock Option	\$0	\$0	\$0
Value Realized on Vesting of Stock	\$0	\$0	\$0
TOTAL REALIZED EQUITY COMPENSATION	\$0	\$0	\$0

Proxy Date: 30 Mar 2012 Annual Meeting Date: 16 May 2012 Equity Reserves: 15.84% Stock Option Run Rate: 2.21%


Human Genome Sciences, Inc.

HGSI NASDAQ

Biotechnology

Market Capitalization USD:

\$2,401.94 mm



Peer Comparisons (TRBC) =Biotechnology

Total Summary CEO Compensation

Ticker	Company Name	2009 2010		2011	Market Cap
HGSI	Human Genome Sciences, Inc.	\$1,911,601	\$9,855,323	\$7,056,323	\$2,401,935,891
LIFE	Life Technologies Corporation	\$4,508,854	\$11,498,009	\$10,897,630	\$6,935,123,147
REGN	Regeneron Pharmaceuticals, Inc.	\$6,349,308	\$7,587,555		\$5,332,669,109
CVD	Covance Inc.	\$5,285,503	\$5,926,949	\$7,192,620	\$2,760,817,754
TECH	Techne Corporation	\$261,872	\$258,256		\$2,519,608,432
UTHR	United Therapeutics Corporation	\$17,591,098	\$17,620,808		\$2,186,289,296
SGEN	Seattle Genetics, Inc.	\$2,533,249	\$3,217,344	\$4,893,175	\$2,184,471,366

To insure consistency, peer comparisons are based on a combination of TRBC Industry and Sector classifications and company market caps.

Missing peer pay figures for 2011 are due to differences in company filing schedules.

Pay Peer Group

Alexion Pharmaceuticals, Celgene, Regeneron Pharmaceuticals, Amylin Pharmaceuticals, Cephalon, Seattle Genetics, Biogen Idec, Dendreon, United Therapeutics, BioMarin Pharmaceuticals, Onyx Pharmaceuticals, Vertex Pharmaceuticals.

Performance Peer Group

NA

COMPENSATION COMMITTEE MEMBERS									
Director	Membership	Age	Gender	Tenure	Independence				
Augustine Lawlor	Chairman	55	Male	8	Outside				
Argeris N. Karabelas	Member	59	Male	10	Outside				
Colin Goddard	Member	52	Male	2	Outside				
John L. LaMattina	Member	62	Male	4	Outside				